BRAF mutation less common among patients with melanoma in Ireland

April 8, 2013

The BRAF mutation believed to drive disease in about half of patients with melanoma was found to occur at a significantly lower frequency in patients with melanoma in Ireland, according to data presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10.

The study, which included two independent cohorts of patients in Europe, revealed that only about 20 percent of a cohort of Irish patients with melanoma harbored a BRAF mutation.

"The clinical approval of a BRAF inhibitor that blocks the function of the mutant BRAF protein is currently one of the most promising approaches to treat metastatic melanoma," said William M. Gallagher, Ph.D., associate professor of at the UCD Conway Institute in Dublin, Ireland. "The observation of a reduced BRAF in Irish patients directly influences future for these patients."

Gallagher and colleagues investigated cancer-related changes in 33 known to be of key importance in . They evaluated two independent cohorts of patients with melanoma, including 94 patients from Ireland and 60 patients from Belgium.

Researchers found that 21 percent of patients with melanoma from Ireland had a BRAF mutation compared with 52 percent of the Belgian patients.

The currently approved BRAF inhibitor specifically targets the BRAFV600E mutation; therefore, the researchers also analyzed the percentage of patients carrying this specific BRAF mutation. They found that 19 percent of the Irish patients had the BRAFV600E mutation compared with 43 percent of the Belgian patients. They found similar results after analyzing tumor tissue from three additional independent cohorts of patients with melanoma from Ireland. In these three groups of 137 patients, 79 patients and 34 patients, the researchers found the BRAFV600E mutation in 21 percent, 20 percent and 32 percent of patients, respectively.

"Treatment with the clinically approved BRAF inhibitor that blocks the function of the mutant BRAF will only be applicable to patients who possess the relevant BRAFV600E mutation," Gallagher said. "As a result, the majority of Irish patients with melanoma will not benefit from this therapy and are currently left without good alternative treatment possibilities."

Although the exact reason for this difference is unknown, Gallagher offered some explanations. First, it is known that BRAF and NRAS mutations are mutually exclusive, and he and his colleagues found a higher rate of NRAS mutations among the Irish patients compared with the patients from Belgium (21 percent versus 13 percent).

In addition, 12 percent of Irish patients had a mutation in the c-MET gene; none of the Belgian patients did. A mutation in c-MET has rarely been found in melanoma before, according to Gallagher.

"This study shows that the molecular biology underlying can change in different demographic areas," Gallagher said. "Hence, to be able to give the best possible treatment, we need to take into account the molecular variations, or genomic landscape, contributing to tumor development and progression between different populations."

Explore further: New drug, Vemurafenib, doubles survival of metastatic melanoma patients

Related Stories

New drug, Vemurafenib, doubles survival of metastatic melanoma patients

March 1, 2012
A report published this week in the New England Journal of Medicine shows that the 50 percent of metastatic melanoma patients with a specific genetic mutation benefit from the drug Vemurafenib – increasing median survival ...

Uncommon BRAF mutation in melanoma sensitive to MEK inhibitor drug therapy

July 16, 2012
An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to MEK inhibitor drugs, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation.

Second mutation in BRAF-mutated melanoma doesn't contribute to resistance

April 1, 2012
A second mutation found in the tumors of patients with BRAF-mutated metastatic melanoma does not contribute to resistance to BRAF inhibitor drugs, a finding that runs counter to what scientists expected to be true.

Response rate high for some patients with metastatic melanoma treated with vemurafenib

March 16, 2012
An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase ...

New drug shrinks brain tumours in melanoma patients

October 8, 2012
(Medical Xpress)—Australian researchers have given hope to patients with advanced melanoma by showing that a new drug targeting a common mutation in melanoma successfully shrank tumours that had spread to the brain.

New drug shrinks brain tumours in melanoma patients

May 21, 2012
(Medical Xpress) -- Australian researchers have reported promising results with a new drug that shrinks brain tumours in melanoma patients. Their findings are published in The Lancet medical journal today.

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.